Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular ...

VEGF is a mediator in the pathogenesis of certain eye conditions, including wet age-related macular degeneration (AMD), diabetic retinopathy and macular oedema secondary to retinal vein occlusions.

Background: Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment ...

DME is characterised by swelling in the macula due to leaking ... Laser treatment, specifically focal/grid macular laser ...

Roche’s ready-to-use drug is indicated for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), ...

The study confirmed that Afqlir has equivalent efficacy and comparable safety to its reference medicine, Eylea.

MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the Phase IIb/III BRUNELLO clinical trial ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).

cataract operation) or Yag procedure with the risk of further aggravating the macular oedema, intra-ocular pressure > 25 mmHg or any established glaucoma patient, ocular or systemic infection ...